INSTRUCTIONS

We encourage you to use Adobe’s editing tools (please see the next page for instructions). If this is not possible, please (i) reply to this message and send a list of corrections (in an email or as an attachment (either as a Word.doc or as a scan)) that lists each change in the following manner: line number, current text, change to be made, or (ii) print out the proof, mark your corrections clearly in black ink, and fax it to [+44 (0) 1865 313489]. Please do not send corrections as track changed Word documents.

Changes should be corrections of typographical errors only. Changes that contradict journal style will not be made.

These proofs are for checking purposes only. They should not be considered as final publication format. The proof must not be used for any other purpose. In particular we request that you: do not post them on your personal/institutional web site, and do not print and distribute multiple copies (please use the attached offprint order form). Neither excerpts nor all of the article should be included in other publications written or edited by yourself until the final version has been published and the full citation details are available. You will be sent these when the article is published.

1. **Licence to Publish:** If you have not already done so, please also complete and return the Licence to Publish form by fax or email attachment. Please also send a hard copy by mail.

2. **Permissions:** Permission to reproduce any third party material in your paper should have been obtained prior to acceptance. If your paper contains figures or text that require permission to reproduce, please inform me immediately by email.

3. **Author groups:** Please check that all names have been spelled correctly and appear in the correct order. Please also check that all initials are present. Please check that the author surnames (family name) have been correctly identified by a pink background. If this is incorrect, please identify the full surname of the relevant authors. Occasionally, the distinction between surnames and forenames can be ambiguous, and this is to ensure that the authors’ full surnames and forenames are tagged correctly, for accurate indexing online.

4. **Figures:** Figures have been placed as close as possible to their first citation. Please check that they are complete and that the correct figure legend is present. Figures in the proof are low resolution versions that will be replaced with high resolution versions when the journal is printed.

5. **Missing elements:** Please check that the text is complete and that all figures, tables and their legends are included.

6. **URLs:** Please check that all web addresses cited in the text, footnotes and reference list are up-to-date, and please provide a ‘last accessed’ date for each URL.

7. **Funding:** Any funding used while completing this work should be highlighted in a separate Funding section. Please ensure that you use the full official name of the funding body.

8. **Conflict of interest:** All authors must make a formal statement indicating any potential conflict of interest that might constitute an embarrassment to any of the authors if it were not to be declared and were to emerge after publication. Such conflicts might include, but are not limited to, shareholding in or receipt of a grant or consultancy fee from a company whose product features in the submitted manuscript or which manufactures a competing product. The following statement has been added to your proof: ‘Conflict of Interest: none declared’. If this is incorrect please supply the necessary text to identify the conflict of interest.
MAKING CORRECTIONS TO YOUR PROOF

These instructions show you how to mark changes or add notes to the document using the Adobe Acrobat Professional version 7.0 (or onwards) or Adobe Reader 8 (or onwards). To check what version you are using go to Help then About. The latest version of Adobe Reader is available for free from get.adobe.com/reader.

For additional help please use the Help function or, if you have Adobe Acrobat Professional 7.0 (or onwards), go to http://www.adobe.com/education/pdf/acrobat_curriculum7/acrobat7_lesson04.pdf

Displaying the toolbars

Adobe Reader 8: Select Tools, Comments & Markup, Show Comments and Markup Toolbar. If this option is not available, please let me know so that I can enable it for you.

Acrobat Professional 7: Select Tools, Commenting, Show Commenting Toolbar.

Adobe Reader 10: To edit the galley proofs, use the comments tab at the top right corner.

Using Text Edits

This is the quickest, simplest and easiest method both to make corrections, and for your corrections to be transferred and checked.

1. Click Text Edits
2. Select the text to be annotated or place your cursor at the insertion point.
3. Click the Text Edits drop down arrow and select the required action.

You can also right click on selected text for a range of commenting options.

Pop up Notes

With Text Edits and other markup, it is possible to add notes. In some cases (e.g. inserting or replacing text), a pop-up note is displayed automatically.

To display the pop-up note for other markup, right click on the annotation on the document and selecting Open Pop-Up Note.

To move a note, click and drag on the title area.

To resize of the note, click and drag on the bottom right corner.

To close the note, click on the cross in the top right hand corner.

To delete an edit, right click on it and select Delete. The edit and associated note will be removed.

SAVING COMMENTS

In order to save your comments and notes, you need to save the file (File, Save) when you close the document. A full list of the comments and edits you have made can be viewed by clicking on the Comments tab in the bottom-left-hand corner of the PDF.
Author Query Form

Journal : Clinical Infectious Diseases

Article doi : 10.1093/cid/cir513

Article title : Syphilis Treatment in the HIV-Infected Patient: Follow the Guidelines

First Author : Frédéric Frippiat

Corr. Author : Frédéric Frippiat

AUTHOR QUERIES - TO BE ANSWERED BY THE CORRESPONDING AUTHOR

The following queries have arisen during the typesetting of your manuscript. Please answer these queries by marking the required corrections at the appropriate point in the text.

There are no queries for this article.
Correspondence

Syphilis Treatment in the HIV-Infected Patient: Follow the Guidelines

To the Editor—We have read with great interest the case report by Haitz and Tyring published in the journal as a Photo Quiz, describing an unusual presentation of secondary syphilis mimicking a herald plaque in a human immunodeficiency virus (HIV)–positive adult patient [1]. However, we disagree with the authors about the treatment. The patient received an intramuscular injection of benzathine penicillin (2.4 million IU) weekly for 3 weeks, because of “the higher tendency of treatment failure with a single injection in immunocompromised patients.” To justify this decision, the authors quoted—as the most recent reference—Kent et al [2], who published an update on syphilis in 2008. However, Kent et al [2] concluded that “Clinicians should be aware of the signs and symptoms of syphilis as well as current guidelines for the management and treatment of this disease.” If we read the most recent guidelines, from the United Kingdom (2008), the United States (2009), and Europe (2009), it is clear that HIV-infected individuals should receive the same treatment regimen as persons without HIV infection, namely, a single injection of benzathine penicillin (2.4 million IU) for primary and secondary syphilis [3–5]. It is true that previous US guidelines, published in 2006 [6], mentioned that “some specialists recommend additional treatment for primary and secondary syphilis—three intramuscular injections of benzathine penicillin G (2.4 million U) instead of one injection,” but this recommendation is not supported in the 2009 US guidelines nor in several recent large reviews about this topic, including ours [3, 7–9]. In conclusion, despite some controversies, treatment of syphilis should be the same in HIV-infected patients as in the general population, and careful follow-up is essential to detect potential treatment failure or disease progression.

Acknowledgments

Potential conflict of interest. All authors: No reported conflicts.

References


Frédéric Frippiat and Michel Moutschen
Division of Infectious Diseases and Immunology, Department of Internal Medicine, Centre Hospitalier Universitaire de Liège, Liège, Belgium

Correspondence: Frédéric Frippiat, MD, Department of Internal Medicine, CHU Sart Tilman B35, 4000 Liège, Belgium (f.frippiat@chu.ulg.ac.be).